Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary effusion lymphoma.

Yi-Bin Chen1, Aliyah Rahemtullah, Ephraim Hochberg

  • 1Dana-Faber Cancer Institute, Boston, Massachusetts, USA.

The Oncologist
|May 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Recrudescence of a FLT3 wild-type CMML clone after allogeneic stem cell transplant for FLT3-ITD acute myeloid leukemia.

The oncologist·2026
Same author

Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines.

Transplantation and cellular therapy·2026
Same author

Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.

Blood immunology & cellular therapy·2026
Same author

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Target trial emulation studies in oncology: a comprehensive analysis.

The oncologist·2026
Same journal

Durable Response to Sotorasib in KRAS G12C-Mutant Intrahepatic Cholangiocarcinoma: A Case Report.

The oncologist·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
See all related articles

Primary effusion lymphoma (PEL), a rare HIV-associated cancer, affects body cavities and is linked to human herpesvirus 8. Current treatments offer a poor prognosis, highlighting the need for targeted therapies.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Primary effusion lymphoma (PEL) is a rare non-Hodgkin's lymphoma (NHL) associated with HIV.
  • PEL uniquely arises in body cavities like the pleura, pericardium, and peritoneum.
  • PEL cells exhibit variable morphology, a null lymphocyte immunophenotype, and human herpesvirus 8 (HHV-8) infection.

Purpose of the Study:

  • To summarize the characteristics of Primary Effusion Lymphoma.
  • To discuss current treatment strategies and prognosis.
  • To highlight the need for further research into HHV-8 oncogenesis.

Main Methods:

  • Literature review of PEL characteristics.
  • Analysis of treatment protocols for HIV-associated NHL.
  • Review of HHV-8's role in oncogenesis.

Related Experiment Videos

Main Results:

  • PEL accounts for approximately 4% of HIV-associated NHL.
  • Standard treatment involves CHOP chemotherapy and antiretroviral therapy.
  • Median survival time for PEL is approximately 6 months.

Conclusions:

  • PEL is an aggressive malignancy with a poor prognosis.
  • Understanding HHV-8's molecular oncogenic mechanisms is crucial.
  • Development of targeted therapies is needed for improved outcomes.